Implications of Early Treatment for Parkinson’s Disease [CME/CPE]
Release date: March 15, 2010 | Expiration date: March 31, 2011 Estimated time to complete activity: 2.5 hours Type of CE Activity: Knowledge-based | Media: Journal supplement
This activity is supported by an educational grant from Teva Neurosciences, Inc.
The audience for this supplement consists of medical directors, pharmacy directors, pharmacy and therapeutic committee members, and healthcare providers who oversee the care of patients with Parkinson’s disease.
Statement of Educational Need/Program Overview
This educational activity will address knowledge and practice gaps that may prevent clinicians from achieving the best possible outcomes in the care of patients with Parkinson’s disease (PD).
PD is a chronic neurodegenerative disease for which current standard treatment is generally limited to symptomatic therapies. Unfortunately, the most common symptomatic therapy, levodopa, is associated with significant side effects; therefore, its use is typically delayed until functional impairment emerges in the PD patient. Because of this delay, there are additional burdens set upon both the patient and the healthcare system.
There are existing and emerging treatments and strategies that have the potential to improve outcomes and delay disease progression. It is the goal of this program to provide practitioners with knowledge of the overall impact of PD and early treatment, methods for identification and diagnosis of patients with PD, and evidence-based strategies for early treatment of PD.
After completing this activity, the participant should be able to:
Describe the primary rationales for early diagnosis and treatment of Parkinson’s disease (PD).
Discuss the appropriate role of levodopa, dopamine agonists, and monoamine oxidase type B inhibitors in the early treatment of PD.
Explain the importance of treating PD-related comorbidities to improve quality of life and delay functional impairment.
Describe how appropriate early treatment can delay symptoms and thereby lower long-term costs of treatment.
Discuss PD risk factors and techniques for differential diagnosis.
According to the disclosure policies of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Physician Continuing Medical Education Accreditation Statement / Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the University of Cincinnati. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education Accreditation Statement / Credit Designation
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.5 contact hours (0.25 CEUs) under the ACPE universal program number of 0290-9999-10-009-H01-P. This program is available for CE credit through March 31, 2011.
Faculty Jack J. Chen, PharmD
Associate Professor of Neurology, Loma Linda University - Loma Linda, CA
Robert A. Hauser, MD, MBA
Professor of Neurology, Molecular Pharmacology and Physiology
Director, Parkinson’s Disease and Movement Disorders Center, University of South Florida - Tampa, FL
Kelly E. Lyons, PhD
Research Associate Professor of Neurology, University of Kansas Medical Center
Director of Research and Education, Parkinson’s Disease and Movement Disorder Center - Kansas City, Kansas
Rajesh Pahwa, MD
Laverne and Joyce Rider, Professor of Neurology
Director, Parkinson’s Disease and Movement Disorder Center, University of Kansas Medical Center - Kansas City, KS
These faculty have disclosed the following relevant commercial financial relationsips or affiliations in the past 12 months.
Jack J. Chen, PharmD
Robert A. Hauser, MD, MBA
Honoraria/lecturer: Allergan Neuroscience, Biogen Idec, Boehringer Ingelheim, Embryon, GE Healthcare, Genzyme, GlaxoSmithKline, Impax, Ipsen Pharmaceuticals, Kyowa Pharmaceutical, Merck Serono International, Novartis, Quintiles, Santhera, Schering Plough, Solvay, Synosia Therapeutics, Teva Neuroscience, UCB, Xenoport
Kelly E. Lyons, PhD
Consultant/advisory board/honoraria: Teva
The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose. Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, NJ.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
System Requirements PC-based participants Required: Windows® 7, Vista, XP, 2003 Server or 2000
Macintosh®-based participants Required: Mac OS® X 10.4.11 (Tiger®) or newer